Integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma (IELSG52)

Research summary

Already existing and coded tumor biological material from the lymph node biopsy and personal health-related data of patients who have been diagnosed with NMZL will be collected retrospectively.The value of the expected results of the IELSG52 study are: (i) to inform on diagnosis and prognosis of NMZL; (ii) to allow selection of optimal therapy; and (iii) to provide a biology based framework on which to design and interpret clinical trials

Principal Investigator

Dr Danmei Xu

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

335163